EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Peripheral Muscle Function and Body Composition in People With Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: A Cross‐Sectional Single‐Centre Study

Lauren J Clayton, Anthony I Shepherd, Jo Corbett, Mathieu Gruet, Gary Connett, Mark Allenby, Julian Legg, Thomas Daniels, Don S Urquhart, Zoe L Saynor

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.71044 ↗

At a glance

Journal article in Pediatric Pulmonology, 2025. Written by Lauren J Clayton and 9 co-authors. Institution: School of Psychology, Sport and Health Science, Faculty of Science and Health, University of Portsmouth, Portsmouth, UK. Major MEDLINE topics: Cystic Fibrosis, Body Composition, Aminophenols, Quinolones. Cited 7 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY 4.0). Funded by: This study was supported by Cystic Fibrosis Warriors Charity (No. 1178063)..

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

People with cystic fibrosis (pwCF) often have multifactorial peripheral muscle abnormalities attributed to, for example, malnutrition, steroid use, altered redox balance and, potentially, CF‐specific intrinsic alterations. Malnutrition in CF now includes an increasing prevalence of overweight and obesity, particularly in those receiving CF transmembrane conductance regulator (CFTR) modulator therapy (CFTRm). We aimed to characterise peripheral muscle function and body composition in pwCF on Elexacaftor/Tezacaftor/Ivacaftor (ETI) CFTRm, compared to healthy controls.

Methods

Fifteen pwCF on ETI, and 15 healthy age‐ and sex‐matched controls (CON), underwent whole‐body dual‐energy X‐ray absorptiometry scans, and a comprehensive evaluation of peripheral muscle function. Tests included quadriceps maximal isometric force measurement, an intermittent isometric quadriceps fatiguing protocol, handgrip strength dynamometry, squat jump height assessment, and 1‐min sit‐to‐stand testing.

Results

No significant differences in quadriceps maximal isometric force (CON: 181.60 ± 92.90 Nm vs. CF: 146.15 ± 52.48 Nm, p = 0.21, d = 0.47), handgrip strength (CON: 34 ± 15 kg vs. CF: 31 ± 11 kg, p = 0.62, d = 0.18), peripheral muscle endurance, fatigue, or power were observed between the groups. Moreover, no significant differences in whole‐body, trunk or limb lean mass, fat‐free mass, fat mass, or whole‐body bone mineral density were evident.

Conclusion

Comparable peripheral muscle mass and function has been demonstrated in pwCF on ETI, albeit a group with good lung function. Research is needed to confirm these findings longitudinally in pwCF, including those with more severe lung disease, who are less physically active, and have less optimal nutrition and exercise support.

Subjects

MeSH terms (MEDLINE)

Cystic FibrosisBody CompositionAminophenolsQuinolonesBenzodioxolesIndolesHumansMaleCross-Sectional StudiesFemaleAdultYoung AdultAbsorptiometry, PhotonAdolescentPyridinesPyrazolesMuscle StrengthCase-Control StudiesDrug CombinationsHand StrengthPyrrolidinesQuadriceps Muscle

Author keywords

cystic fibrosis transmembrane conductance regulatormodulatormuscle strengthobesityskeletal muscle

Substances

AminophenolsQuinolonesBenzodioxolesivacaftorIndolesPyridineselexacaftortezacaftorPyrazolesDrug Combinations

Authors and institutions

  • School of Psychology, Sport and Health Science, Faculty of Science and Health, University of Portsmouth, Portsmouth, UK.
  • University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Université de Toulon, Toulon, France.
  • National Institute for Health and Care Research, Southampton Biomedical Research Centre, Southampton, UK.
  • Department of Paediatric Respiratory and Sleep Medicine, Royal Hospital for Children and Young People, Edinburgh, Scotland, UK.
  • Department of Child Life and Health, University of Edinburgh, Scotland, UK.

Funding

  • This study was supported by Cystic Fibrosis Warriors Charity (No. 1178063).

Cite

APA

Clayton, L. J., Shepherd, A. I., Corbett, J., Gruet, M., Connett, G., Allenby, M., Legg, J., Daniels, T., Urquhart, D. S., & Saynor, Z. L. (2025). Peripheral Muscle Function and Body Composition in People With Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: A Cross‐Sectional Single‐Centre Study. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71044

Vancouver

Clayton LJ, Shepherd AI, Corbett J, Gruet M, Connett G, Allenby M, et al. Peripheral Muscle Function and Body Composition in People With Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: A Cross‐Sectional Single‐Centre Study. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71044

BibTeX
@article{Clayton2025,
  author = {Clayton, Lauren J and Shepherd, Anthony I and Corbett, Jo and Gruet, Mathieu and Connett, Gary and Allenby, Mark and Legg, Julian and Daniels, Thomas and Urquhart, Don S and Saynor, Zoe L},
  title = {Peripheral Muscle Function and Body Composition in People With Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: A Cross‐Sectional Single‐Centre Study},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.71044}
}
Start for free →